Almorexant
A dual Orexin receptor OX1/OX2 antagonist with Ki of 1.3/0.17 nM for hOX1/hOX2 respectively; selectively inhibits the functional consequences of OX1 and OX2 receptor activation, such as intracellular Ca2+ mobilization.Sleep Disorder Phase 3 Discontinued (In Vitro) :Almorexant (1 μM) promotes tyrosine phosphorylation of SHP2/OX1R complex.Almorexant (1 μM) inhibits the cellular growth of AsPC-1 cells. (In Vivo) :Almorexant (1.8 μmol/kg, 100 μL; IP, daily) reduces the volume of tumors.Almorexant (300 mg/kg, PO, once) can help rats to be fully capable of spatial and avoidance learning.Almorexant (30-300 mg/kg) dose-dependently increases rapid eye movement (REM) and non-REM (NREM) sleep and decreases wakefulness apparently without inducing either cataplexy18 or deficits in next-day performance.
Product Specifications
CAS Number
871224-64-5
Product Name Alternative
ACT-078573 | ACT 078573 | ACT078573
Purity
>98% (HPLC)
Solubility
10 mM in DMSO
Smiles
CNC (=O) [C@H] (N1CCc2cc (OC) c (OC) cc2[C@@H]1CCc3ccc (cc3) C (F) (F) F) c4ccccc4
Molecular Formula
C29H31F3N2O3
Molecular Weight
512.5632
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
2 (1H) -Isoquinolineacetamide, 3,4-dihydro-6,7-dimethoxy-N-methyl-α-phenyl-1-[2-[4- (trifluoromethyl) phenyl]ethyl]-, (αR,1S) -
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
PR Set7 (SET8, SET Domain Containing 8, SET Domain-containing Protein 8, SET Domain Containing Lysine Methyltransferase 8, SET Domain-containing (Lysine Methyltransferase) 8, SETD8, H4 K20 Specific Histone Methyltransferase, H4-K20-HMTase SETD8, PR/SET Domain-containing Protein 07, PrSET7, Pr-SET7, PR/SET07, PR/SET Domain-containing Protein 8, SET07) (PE)
Anti-IL32 Antibody Picoband® Fluoro647 Conjugated
